[Form 4] Septerna, Inc. Insider Trading Activity
Septerna, Inc. reported a compensatory stock option grant to its Chief Medical Officer, Kim Jae B. The award is a stock option to purchase 55,000 shares of common stock at an exercise price of $11.70 per share. The option grant date is shown as 08/07/2025 and the option expires on 08/06/2035. The option vests in a two-step schedule: 2/48ths of the shares become exercisable on October 1, 2025, with the remaining shares vesting in 46 substantially equal monthly installments thereafter, subject to continuous service. The shares are reported as directly owned following the transaction. This filing documents the terms and vesting timetable of the derivative award to an executive officer.
Septerna, Inc. ha comunicato la concessione di un'opzione su azioni a titolo compensativo al suo Direttore medico, Kim Jae B. Il premio consiste in un'opzione per acquistare 55,000 azioni ordinarie al prezzo di esercizio di $11.70 per azione. La data di attribuzione dell'opzione 猫 indicata come 7 agosto 2025 e l'opzione scade il 6 agosto 2035. L'opzione matura con un piano in due fasi: 2/48esimi delle azioni diventano esercitabili il 1 ottobre 2025, mentre le restanti azioni maturano in 46 rate mensili sostanzialmente uguali successivamente, subordinatamente alla continuit脿 del servizio. Le azioni risultano di propriet脿 direttamente dopo la transazione. Questa comunicazione documenta i termini e il calendario di maturazione del premio derivato concesso a un dirigente.
Septerna, Inc. inform贸 una concesi贸n de opciones sobre acciones a t铆tulo compensatorio a su Director M茅dico, Kim Jae B. La adjudicaci贸n consiste en una opci贸n para comprar 55,000 acciones ordinarias a un precio de ejercicio de $11.70 por acci贸n. La fecha de concesi贸n figura como 7 de agosto de 2025 y la opci贸n vence el 6 de agosto de 2035. La opci贸n adquiere derechos seg煤n un calendario en dos fases: 2/48avos de las acciones se vuelven ejercitables el 1 de octubre de 2025, y las acciones restantes se consolidan en 46 cuotas mensuales sustancialmente iguales posteriormente, sujeto a la continuidad del servicio. Tras la transacci贸n, las acciones se informan como de propiedad directa. Este documento recoge los t茅rminos y el calendario de adquisici贸n de este instrumento derivado otorgado a un ejecutivo.
Septerna, Inc.電� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer) 旯�鞛� B.鞐愱矊 氤挫儊靹� 鞀ろ啞鞓奠厴鞚� 攵�鞐枅雼り碃 氤搓碃頄堨姷雼堧嫟. 靾橃棳霅� 鞓奠厴鞚� 氤错喌欤� 55,000欤茧ゼ 欤茧嫻 頄夓偓臧�瓴� $11.70鞐� 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ鞛呺媹雼�. 鞓奠厴 攵�鞐澕鞚� 2025雲� 8鞗� 7鞚�搿� 旮办灛霅橃柎 鞛堨溂氅�, 鞓奠厴 毵岆鞚检潃 2035雲� 8鞗� 6鞚�鞛呺媹雼�. 鞓奠厴鞚� 臧�霌�(vesting)鞚� 霊� 雼硠搿� 鞚措（鞏挫雼堧嫟: 48攵勳潣 2鞐� 頃措嫻頃橂姅 欤检嫕鞚� 2025雲� 10鞗� 1鞚�鞐� 頄夓偓 臧�電ロ晿瓴� 霅橂┌, 雮橂ǜ歆� 欤检嫕鞚� 鞐办啀 攴茧毳� 鞝勳牅搿� 鞚错泟鞐� 鞁れ鞝侅溂搿� 霃欖澕頃� 46須岇潣 鞗旊硠 攵勴暊搿� 氩犾姢韺呺惄雼堧嫟. 瓯半灅 頉� 頃措嫻 欤检嫕鞚� 歆侅为 氤挫湢搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞚� 鞝滌稖靹滊姅 鞛勳洂鞐愱矊 攵�鞐悳 韺岇儩 氤挫儊鞚� 臁瓣贝瓿� 氩犾姢韺� 鞚检爼鞚� 氍胳劀頇旐暕雼堧嫟.
Septerna, Inc. a d茅clar茅 l'attribution d'une option d'achat d'actions 脿 titre compensatoire 脿 son directeur m茅dical, Kim Jae B. L'attribution porte sur une option d'achat de 55,000 actions ordinaires au prix d'exercice de $11.70 par action. La date d'octroi de l'option est indiqu茅e comme le 7 ao没t 2025 et l'option expire le 6 ao没t 2035. L'option acquiert des droits selon un calendrier en deux 茅tapes: 2/48猫尘别蝉 des actions deviennent exer莽ables le 1er octobre 2025, les actions restantes acqu茅rant ensuite des droits en 46 versements mensuels sensiblement 茅gaux, sous r茅serve de la continuit茅 du service. Apr猫s la transaction, les actions sont signal茅es comme d茅tenues directement. Ce d茅p么t documente les modalit茅s et le calendrier d'acquisition de cette r茅mun茅ration d茅riv茅e accord茅e 脿 un dirigeant.
Septerna, Inc. meldete die Gew盲hrung einer verg眉tungsbezogenen Aktienoption an ihren Chief Medical Officer, Kim Jae B. Der Zuschuss ist eine Option zum Kauf von 55,000 Stammaktien zum Aus眉bungspreis von $11.70 je Aktie. Das Datum der Optionsgew盲hrung ist mit 7. August 2025 angegeben, die Option l盲uft am 6. August 2035 ab. Die Aus眉bungsberechtigung erfolgt nach einem zweistufigen Plan: 2/48stel der Aktien werden am 1. Oktober 2025 aus眉bbar, die verbleibenden Aktien werden anschlie脽end in 46 im Wesentlichen gleichm盲脽igen monatlichen Raten 眉bertragen, vorbehaltlich fortgesetzter Dienstzeit. Nach der Transaktion werden die Aktien als direkt im Besitz gemeldet. Diese Einreichung dokumentiert die Bedingungen und den Vesting-Zeitplan der an einen leitenden Angestellten gew盲hrten Derivatpr盲mie.
- 55,000-share stock option grant is explicitly documented, including exercise price and expiration date
- Vesting schedule is clearly defined: 2/48ths on October 1, 2025 then 46 monthly installments, providing transparency on service conditions
- None.
Insights
TL;DR: Routine officer equity grant: 55,000 options at $11.70 with a standard service-based vesting schedule, moderate duration to expiration.
The reported transaction is a conventional option award to an executive officer. Key facts are a 55,000-share option grant with an $11.70 exercise price and an August 6, 2035 expiration. Vesting begins with a small initial tranche on October 1, 2025 and continues monthly, tying realization to continued service. For investors, this is primarily a compensation disclosure; it does not itself change outstanding common shares until options are exercised.
TL;DR: Governance disclosure shows a service-contingent equity award to a named officer with clear vesting terms and direct ownership reporting.
The form discloses material grant terms transparently: option quantity, $11.70 exercise price, vesting schedule (2/48ths at first vest date then monthly installments), and a defined expiration date. The reporting person is identified as the Chief Medical Officer and the ownership form is direct. This meets standard Section 16 reporting expectations for executive compensation events; the filing does not indicate any atypical acceleration provisions or third-party arrangements.
Septerna, Inc. ha comunicato la concessione di un'opzione su azioni a titolo compensativo al suo Direttore medico, Kim Jae B. Il premio consiste in un'opzione per acquistare 55,000 azioni ordinarie al prezzo di esercizio di $11.70 per azione. La data di attribuzione dell'opzione 猫 indicata come 7 agosto 2025 e l'opzione scade il 6 agosto 2035. L'opzione matura con un piano in due fasi: 2/48esimi delle azioni diventano esercitabili il 1 ottobre 2025, mentre le restanti azioni maturano in 46 rate mensili sostanzialmente uguali successivamente, subordinatamente alla continuit脿 del servizio. Le azioni risultano di propriet脿 direttamente dopo la transazione. Questa comunicazione documenta i termini e il calendario di maturazione del premio derivato concesso a un dirigente.
Septerna, Inc. inform贸 una concesi贸n de opciones sobre acciones a t铆tulo compensatorio a su Director M茅dico, Kim Jae B. La adjudicaci贸n consiste en una opci贸n para comprar 55,000 acciones ordinarias a un precio de ejercicio de $11.70 por acci贸n. La fecha de concesi贸n figura como 7 de agosto de 2025 y la opci贸n vence el 6 de agosto de 2035. La opci贸n adquiere derechos seg煤n un calendario en dos fases: 2/48avos de las acciones se vuelven ejercitables el 1 de octubre de 2025, y las acciones restantes se consolidan en 46 cuotas mensuales sustancialmente iguales posteriormente, sujeto a la continuidad del servicio. Tras la transacci贸n, las acciones se informan como de propiedad directa. Este documento recoge los t茅rminos y el calendario de adquisici贸n de este instrumento derivado otorgado a un ejecutivo.
Septerna, Inc.電� 斓滉碃鞚橂毂呾瀯鞛�(Chief Medical Officer) 旯�鞛� B.鞐愱矊 氤挫儊靹� 鞀ろ啞鞓奠厴鞚� 攵�鞐枅雼り碃 氤搓碃頄堨姷雼堧嫟. 靾橃棳霅� 鞓奠厴鞚� 氤错喌欤� 55,000欤茧ゼ 欤茧嫻 頄夓偓臧�瓴� $11.70鞐� 毵れ垬頃� 靾� 鞛堧姅 甓岆Μ鞛呺媹雼�. 鞓奠厴 攵�鞐澕鞚� 2025雲� 8鞗� 7鞚�搿� 旮办灛霅橃柎 鞛堨溂氅�, 鞓奠厴 毵岆鞚检潃 2035雲� 8鞗� 6鞚�鞛呺媹雼�. 鞓奠厴鞚� 臧�霌�(vesting)鞚� 霊� 雼硠搿� 鞚措（鞏挫雼堧嫟: 48攵勳潣 2鞐� 頃措嫻頃橂姅 欤检嫕鞚� 2025雲� 10鞗� 1鞚�鞐� 頄夓偓 臧�電ロ晿瓴� 霅橂┌, 雮橂ǜ歆� 欤检嫕鞚� 鞐办啀 攴茧毳� 鞝勳牅搿� 鞚错泟鞐� 鞁れ鞝侅溂搿� 霃欖澕頃� 46須岇潣 鞗旊硠 攵勴暊搿� 氩犾姢韺呺惄雼堧嫟. 瓯半灅 頉� 頃措嫻 欤检嫕鞚� 歆侅为 氤挫湢搿� 氤搓碃霅橃棃鞀惦媹雼�. 鞚� 鞝滌稖靹滊姅 鞛勳洂鞐愱矊 攵�鞐悳 韺岇儩 氤挫儊鞚� 臁瓣贝瓿� 氩犾姢韺� 鞚检爼鞚� 氍胳劀頇旐暕雼堧嫟.
Septerna, Inc. a d茅clar茅 l'attribution d'une option d'achat d'actions 脿 titre compensatoire 脿 son directeur m茅dical, Kim Jae B. L'attribution porte sur une option d'achat de 55,000 actions ordinaires au prix d'exercice de $11.70 par action. La date d'octroi de l'option est indiqu茅e comme le 7 ao没t 2025 et l'option expire le 6 ao没t 2035. L'option acquiert des droits selon un calendrier en deux 茅tapes: 2/48猫尘别蝉 des actions deviennent exer莽ables le 1er octobre 2025, les actions restantes acqu茅rant ensuite des droits en 46 versements mensuels sensiblement 茅gaux, sous r茅serve de la continuit茅 du service. Apr猫s la transaction, les actions sont signal茅es comme d茅tenues directement. Ce d茅p么t documente les modalit茅s et le calendrier d'acquisition de cette r茅mun茅ration d茅riv茅e accord茅e 脿 un dirigeant.
Septerna, Inc. meldete die Gew盲hrung einer verg眉tungsbezogenen Aktienoption an ihren Chief Medical Officer, Kim Jae B. Der Zuschuss ist eine Option zum Kauf von 55,000 Stammaktien zum Aus眉bungspreis von $11.70 je Aktie. Das Datum der Optionsgew盲hrung ist mit 7. August 2025 angegeben, die Option l盲uft am 6. August 2035 ab. Die Aus眉bungsberechtigung erfolgt nach einem zweistufigen Plan: 2/48stel der Aktien werden am 1. Oktober 2025 aus眉bbar, die verbleibenden Aktien werden anschlie脽end in 46 im Wesentlichen gleichm盲脽igen monatlichen Raten 眉bertragen, vorbehaltlich fortgesetzter Dienstzeit. Nach der Transaktion werden die Aktien als direkt im Besitz gemeldet. Diese Einreichung dokumentiert die Bedingungen und den Vesting-Zeitplan der an einen leitenden Angestellten gew盲hrten Derivatpr盲mie.
FAQ
What did Septerna (SEPN) disclose in this Form 4?
When was the transaction dated for the SEPN option grant?
What is the vesting schedule for the options reported on SEPN Form 4?
When do the options expire?
How many shares are beneficially owned following the transaction?
What is the reporting person's role at Septerna?
